2014
DOI: 10.1182/blood-2014-02-556027
|View full text |Cite
|
Sign up to set email alerts
|

TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinins

Abstract: Key Points Cold agglutinin–driven classical pathway activity terminates prior to the initiation of the terminal cascade in CAD patient blood. By inhibiting cold agglutinin–mediated complement deposition on the cellular membrane, TNT003 prevents RBCs from being phagocytosed.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

2
158
0
3

Year Published

2015
2015
2023
2023

Publication Types

Select...
7
1

Relationship

1
7

Authors

Journals

citations
Cited by 129 publications
(163 citation statements)
references
References 40 publications
2
158
0
3
Order By: Relevance
“…TNT003 also efficiently reduced the generation of proinflammatory and vasoactive anaphylatoxins. 33 Moreover, TNT003 efficiently inhibited cold-agglutinin-mediated RBC hemolysis. In a humanized form, TNT003 might be a suitable inhibitor to block complement-mediated RBC destruction in AIHA.…”
mentioning
confidence: 99%
See 2 more Smart Citations
“…TNT003 also efficiently reduced the generation of proinflammatory and vasoactive anaphylatoxins. 33 Moreover, TNT003 efficiently inhibited cold-agglutinin-mediated RBC hemolysis. In a humanized form, TNT003 might be a suitable inhibitor to block complement-mediated RBC destruction in AIHA.…”
mentioning
confidence: 99%
“…In a humanized form, TNT003 might be a suitable inhibitor to block complement-mediated RBC destruction in AIHA. 33 Recently, TNT003 was successfully tested in an in vitro model for antibody-mediated graft rejection (AMR) showing its potency to reduce antibody-mediated classical pathway activation. 67 In addition, plasma-derived C1-inh is currently being tested in clinical trials for its efficacy in preventing AMR in kidney transplantation (clincialtrials.gov identifier: 01147302 and 01134510).…”
mentioning
confidence: 99%
See 1 more Smart Citation
“…Shi, et al Recently showed that a novel serine protease C1s inhibitor could inhibit complement activation by cold agglutinins, the main mechanism of haemolysis in cold agglutinin disease [32]. If flares are unable to be prevented, general anticoagulation may be considered.…”
Section: Discussionmentioning
confidence: 99%
“…I tillegg pågår studier innenfor så varierte områder som sepsis, obstruktiv lungesykdom, inflammatorisk tarmsykdom og ulike former for iskemireperfusjonsskade (5). Også ved noen former for autoimmun hemolytisk anemi og ved akutte hemolytiske transfusjonsreaksjoner er det mulig at komplementhemming kan ha en plass (26,27).…”
Section: Mulige Fremtidige Indikasjonerunclassified